- Home
- APLT vs RNTX Comparison
APLT vs RNTX Comparison
Compare APLT & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLT
- RNTX
- Stock Information
- Founded
- APLT 2016
- RNTX 2001
- Country
- APLT United States
- RNTX United States
- Employees
- APLT N/A
- RNTX N/A
- Industry
- APLT Biotechnology: Pharmaceutical Preparations
- RNTX Biotechnology: Pharmaceutical Preparations
- Sector
- APLT Health Care
- RNTX Health Care
- Exchange
- APLT Nasdaq
- RNTX Nasdaq
- Market Cap
- APLT 37.5M
- RNTX 44.2M
- IPO Year
- APLT 2019
- RNTX N/A
- Fundamental
- Price
- APLT $0.40
- RNTX $1.76
- Analyst Decision
- APLT Buy
- RNTX
- Analyst Count
- APLT 7
- RNTX 0
- Target Price
- APLT $6.10
- RNTX N/A
- AVG Volume (30 Days)
- APLT 1.9M
- RNTX 26.4K
- Earning Date
- APLT 05-20-2025
- RNTX 05-19-2025
- Dividend Yield
- APLT N/A
- RNTX N/A
- EPS Growth
- APLT N/A
- RNTX N/A
- EPS
- APLT N/A
- RNTX N/A
- Revenue
- APLT $455,000.00
- RNTX N/A
- Revenue This Year
- APLT $1,768.13
- RNTX N/A
- Revenue Next Year
- APLT $361.28
- RNTX N/A
- P/E Ratio
- APLT N/A
- RNTX N/A
- Revenue Growth
- APLT N/A
- RNTX N/A
- 52 Week Low
- APLT $0.30
- RNTX $1.35
- 52 Week High
- APLT $10.62
- RNTX $4.40
- Technical
- Relative Strength Index (RSI)
- APLT 46.92
- RNTX N/A
- Support Level
- APLT $0.39
- RNTX N/A
- Resistance Level
- APLT $0.44
- RNTX N/A
- Average True Range (ATR)
- APLT 0.04
- RNTX 0.00
- MACD
- APLT 0.01
- RNTX 0.00
- Stochastic Oscillator
- APLT 45.49
- RNTX 0.00
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
About RNTX Rein Therapeutics Inc. Common Stock
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03, LTI-01, and others.